<DOC>
	<DOC>NCT01755676</DOC>
	<brief_summary>The purpose of this study is to evaluate efficacy of orlistat 60 mg as adjuvant treatment of Obesity in adults.</brief_summary>
	<brief_title>Evaluation of Orlistat as Adjuvant Treatment of Obesity in Adults</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Orlistat</mesh_term>
	<criteria>Signed Informed Consent; Adults Male and Female ≥ 18 years old; Obesity (BMI ≥ 30kg/m2 or ≥ 27 Kg/m2 with associate risk); Pregnancy and Lactation or women without effective contraception; Relevant clinical diseases; Obesity associated to genetic syndrome; Decompensated Diabetes; Psychiatric disorders; Alimentary disorders; Use of: anorectics, herbal weight loss and/or constipation and laxatives, in the past 30 days; Patients using cyclosporine or amiodarone; Patients with bowel disease; Prior bariatric surgery; Anemia; Hemoglobinopathies and coagulopathy; History of cancer in the past five years; Use of corticosteroids, oral or injectable, in the last 30 days.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>